Saga Bio, Inc.

39 Bayberry Ln
Branford, Connecticut 06405

Phone: 203-871-7211

General Information:

Formed in 2022 to develop a sTNFR2 lateral flow device for screening febrile children for Kawasaki Disease with additional uses in resource challenged settings. Mothballed at the end of 2024 when the USA pulled out of the WHO. In summer of 2026 Saga Bio will spin back up as a virtual biotech to develop biotherapeutics and a modified “dead” Fc domain critical for biotherapeutic TNFR2 blockade. Saga Bio has right of first refusal for Johnson/Yale IP. In 2024 Saga received a Blavatnik Award to develop biotherapeutic antibodies against Tmem 273.

Pipeline:
1) Tmem 273 biotherapeutic antibody hc10-6g1 coupled to monomethyl auristatin e (ADC). Tmem 273 is a unique yes/no biomarker for T cells that co-produce IFN-gamma and IL-13 and drive fibrosis in disease including systemic sclerosis and chronic asthma. Biotherapeutic strategy based on depleting Tmem 273 positive T cells. First human investigation of Tmem 273 as a biomarker will be submitted June 2026.

2) TNFR2 biotherapeutic 26C9antibody with an Fc-dead domain. Blocks membrane TNFalpha binding to TNFR2 and alters cytokine profile to a tolerogenic pattern. Likely able to induce tolerance in transplant and autoimmunity.

Research Activities:

Saga Bio will manage CRO research activities when pipeline projects transition from the academic realm to biotech.